标签：million

Product Overview

Cord blood CD34+ cells are known to contain hematopoietic stem and progenitor cells, and are ideal for studies relating to transplantation and stem cells as cord blood derived cells tend to be more naïve than similar cells derived from other tissue sources.

众所周知，脐带血 CD34+ 细胞含有造血干细胞和祖细胞，是与移植和干细胞相关的研究的理想选择，因为脐带血来源的细胞往往比其他组织来源的类似细胞更幼稚。

High Purity and Viability

Lonza cord blood CD34+ cells are isolated from cord blood mononuclear cells (MNCs) via positive immunomagnetic separation and are guaranteed to have a purity of ≥90% as indicated by CD34+ expressing cells. They are guaranteed to contain  ≥1 million viable cells per ampoule. HIV-1 and hepatitis B are not detected for all donors and/or cell lots. A Certificate of Analysis is provided for each cell lot purchased.

Choices in Tissue Source

Cord blood CD34+ cells tend to be more naive than hematopoietic stem cells from other tissue sources. Thus, they can be a great tool when trying to bypass HLA mismatch issues. However, the number of cells available per donor is limited and can pose a challenge in your research. If you are looking for large numbers of hematopoietic stem cells from the same donor, CD34+ cells derived from bone marrow might be a good option.

Lonza guarantees the performance of Clonetics^TM/Poietics^TM cells only if appropriate Clonetics^TM/Poietics^TM media and reagents are used exclusively and the recommended storage and use protocols are followed. Any modifications made to the recommended cell systems including the use of alternative media, reagents or protocols, will void cell and media performance guarantees.

Lonza 脐带血 CD34+ 细胞通过阳性免疫磁性分离从脐带血单核细胞 (MNC) 中分离出来，并保证其纯度≥90%，如 CD34+ 表达细胞所示。它们保证每个安瓿含有≥100万个活细胞。并非所有供体和/或细胞批次都检测到 HIV-1 和乙型肝炎。为购买的每个细胞批次提供分析证书。

组织来源的选择

与其他组织来源的造血干细胞相比，脐带血 CD34+ 细胞往往更幼稚。因此，当试图绕过 HLA 不匹配问题时，它们可以成为一个很好的工具。但是，每个供体可用的细胞数量有限，可能会给您的研究带来挑战。如果您正在寻找来自同一供体的大量造血干细胞，来自骨髓的 CD34+ 细胞可能是一个不错的选择。

只有在专门使用适当的 CloneticsTM/PoieticsTM 培养基和试剂并遵循推荐的储存和使用协议时，Lonza 才能保证 CloneticsTM/PoieticsTM 细胞的性能。对推荐的细胞系统进行的任何修改，包括使用替代培养基、试剂或方案，都将使细胞和培养基性能保证失效。